Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 1.3% – Time to Sell?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) dropped 1.3% during trading on Wednesday . The stock traded as low as $5.98 and last traded at $5.98. Approximately 5,272,832 shares were traded during trading, a decline of 79% from the average daily volume of 25,186,756 shares. The stock had previously closed at $6.06.

Analysts Set New Price Targets

RXRX has been the topic of several research analyst reports. Cowen restated a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Leerink Partners decreased their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Friday, February 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Finally, KeyCorp cut their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $8.25.

Recursion Pharmaceuticals Stock Up 3.6 %

The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The firm has a market cap of $2.47 billion, a price-to-earnings ratio of -4.02 and a beta of 0.85. The firm has a 50 day moving average price of $7.57 and a 200-day moving average price of $7.03.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. During the same period in the previous year, the company posted ($0.42) EPS. The company’s quarterly revenue was down 57.8% compared to the same quarter last year. As a group, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the stock. Integrated Advisors Network LLC lifted its stake in Recursion Pharmaceuticals by 36.8% in the fourth quarter. Integrated Advisors Network LLC now owns 17,588 shares of the company’s stock valued at $119,000 after buying an additional 4,731 shares during the period. GF Fund Management CO. LTD. acquired a new position in Recursion Pharmaceuticals in the fourth quarter valued at about $54,000. CSS LLC IL acquired a new position in Recursion Pharmaceuticals in the fourth quarter valued at about $366,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Recursion Pharmaceuticals by 5.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,259,178 shares of the company’s stock valued at $15,272,000 after buying an additional 118,428 shares during the period. Finally, Vident Advisory LLC acquired a new position in Recursion Pharmaceuticals in the fourth quarter valued at about $80,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.